Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical ...

Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and ...

On the heels of releasing its most capable AI model yet, Google is making some changes to the Gemini team. A new report from ...

As STAT’s Katie Palmer reports in a new story, the lack of standards for collection of this information will make it more ...

Isomorphic Labs, which broke off from Google's DeepMind in 2021, raised $600 million from investors in a new funding round ...

Isomorphic Labs CEO Demis Hassabis discusses $600M funding round, plans for a US office, and expanding into ...

Demis Hassabis, cofounder of DeepMind and 2024 Nobel Laureate, talks to Fortune about his AI drug discovery startup, ...

Though Isomorphic is burning through millions in R&D costs now, investors have high hopes for the potential of AI drug ...

Isomorphic Labs was founded to apply artificial intelligence to drug discovery. The company is led by AI researcher Sir Demis Hassabis.

Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...

Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These ...